Patient-reported outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib: results from the PhALLCON trial.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Ashaye A
  • Shi L
  • Aldoss I
  • Vachhani P
  • Rocha V
  • Papayannidis C
  • Leonard JT
  • Baer MR
  • Ribera JM
  • McCloskey J
  • Wang J
  • Gao S
  • Rane D
  • Guo S

Grupos

Abstract

In the Phase 3 PhALLCON trial (NCT03589326), ponatinib demonstrated superior efficacy and comparable safety profile versus imatinib in adults with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Here we report patient-reported outcomes (PRO) from PhALLCON assessed as exploratory endpoints using the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu) and EQ-5D-5L. Primary PRO domains included FACT-G physical well-being, FACT-Leu subscale (FACT-LeuS), Trial Outcome Index (TOI), FACT-Leu total score, FACT-G total score, and EQ-5D visual analogue scale. Differences in least-squares mean score changes from baseline to the end of induction (EOI)/consolidation (EOC) and time to confirmed improvement/deterioration were analyzed. Overall treatment tolerability was assessed using the FACT-GP5. Analyses included 238 patients (ponatinib 159, imatinib 79) with =1 PRO assessment. Least-squares mean changes from baseline favored ponatinib, with significant and meaningful differences in FACT-LeuS, TOI, and FACT-Leu total score at EOI and across the primary domains except for FACT-LeuS at EOC. Median time to confirmed improvement was shorter with ponatinib versus imatinib for key measures. Ponatinib-treated patients tended to report being less bothered by treatment side effects as assessed by FACT-GP5. These findings highlight ponatinib's potentially favorable impact on health-related quality of life, supporting its use as frontline treatment for Ph+ ALL.

© 2025. The Author(s).

Datos de la publicación

ISSN/ISSNe:
0887-6924, 1476-5551

LEUKEMIA  SPRINGERNATURE

Tipo:
Article
Páginas:
1342-1350
PubMed:
40240572
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
4,030 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 2

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • QUALITY-OF-LIFE; CHRONIC MYELOID-LEUKEMIA; KINASE DOMAIN MUTATIONS; FUNCTIONAL ASSESSMENT; BOSUTINIB SKI-606; CANCER-THERAPY; STANDARD; INHIBITOR; VERSION; SCORES

Compartir